SCHEMBL19552295

SCHEMBL19552295

CN(C)/C=N/S(=O)(=O)c1cc(NC(=O)Cc2ccccc2F)ccc1Br

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNJ6 P48051 4/20 0.51
▸ KCNJ5 P48544 4/20 0.51
▸ KCNJ3 P48549 4/20 0.51
▸ P2RX4 Q99571 3/20 0.47
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ GSTO1 P78417 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ ANO1 Q5XXA6 2/20 0.43
▸ GAA P10253 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42
▸ RORC P51449 1/20 0.42
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19552299 1.00 KCNJ6 (0.51) KCNJ6KCNJ5KCNJ3P2RX4NPC1
SCHEMBL19551508 0.88 KCNJ5 (0.58) KCNJ6KCNJ5KCNJ3P2RX4GSTO1
SCHEMBL19551509 0.88 KCNJ5 (0.58) KCNJ6KCNJ5KCNJ3P2RX4GSTO1
Hydrochloric Acid SCHEMBL19552593 0.87 KCNJ5 (0.57) KCNJ6KCNJ5KCNJ3P2RX4GSTO1
Hydrochloric Acid SCHEMBL19552592 0.87 KCNJ5 (0.57) KCNJ6KCNJ5KCNJ3P2RX4GSTO1
Hydrochloric Acid SCHEMBL30889327 0.87 KCNJ6 (0.56) KCNJ6KCNJ5KCNJ3P2RX4GSTO1
Hydrochloric Acid SCHEMBL29236088 0.87 KCNJ5 (0.56) KCNJ6KCNJ5KCNJ3P2RX4GSTO1
SCHEMBL19551715 0.84 P2RX4 (0.47) KCNJ6KCNJ5KCNJ3P2RX4GSTO1
SCHEMBL19551717 0.84 P2RX4 (0.47) KCNJ6KCNJ5KCNJ3P2RX4GSTO1
SCHEMBL20929119 0.83 RAB9A (0.51) KCNJ6KCNJ5KCNJ3P2RX4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524938-B2 Aromatic sulfonamide derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-13 — — US disclosed
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-10-13 — — US disclosed
EP-3763704-A1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2021-01-13 — — EP disclosed
US-10844016-B2 Aromatic sulfonamide derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-11-24 — — US disclosed
EP-3458443-B1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma AG (DE) 2020-08-19 — — EP disclosed
US-20190119210-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-04-25 — — US disclosed
EP-3458443-A1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2019-03-27 — — EP disclosed
WO-2017191000-A9 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-12-27 — — WO disclosed
WO-2017191000-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119210-A1 AROMATIC SULFONAMIDE DERIVATIVES ARSA, SULT2A1, TPST2 KCNJ6 2337/4885KCNJ5 1892/4885KCNJ3 2802/4885
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES ARSA, SULT2A1, TPST2 KCNJ6 2337/4885KCNJ5 1892/4885KCNJ3 2802/4885
US-11524938-B2 Aromatic sulfonamide derivatives ARSA, SULT2A1, TPST2 KCNJ6 2337/4885KCNJ5 1892/4885KCNJ3 2802/4885
US-10844016-B2 Aromatic sulfonamide derivatives ARSA, SULT2A1, TPST2 KCNJ6 2337/4885KCNJ5 1892/4885KCNJ3 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback